Saturday 17 October 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
4.85
0.51
−9.51%
Follow KYNB
Kyntra Bio Inc (KYNB) P/E ratio
As of 16 October 2026, Kyntra Bio Inc (KYNB) trades at a P/E ratio of 0.1×. Over the past ten years it has ranged from 0.0× (September 2025) to 98.1× (December 2019); the current reading is higher than 87% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.2× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.2× | (0.54%) |
| Mar 2026 | 0.2× | (13.21%) |
| Dec 2025 | 0.2× | (15.71%) |
| Sep 2025 | 0.2× | — |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 98.1×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| COCP Cocrystal Pharma, Inc. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| QNTM Quantum Biopharma Ltd. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| CYAD Celyad SA compare | n/m |
| KYNB Kyntra Bio Inc | 0.1× |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)